Upstream Bio announced that its Phase 2 VALIANT trial of the TSLP‑receptor antagonist verekitug met its primary endpoint, delivering a 56% reduction in annualized asthma exacerbation rate (AAER) with the 100 mg every‑12‑week dose and a 39% reduction with the 400 mg every‑24‑week dose versus placebo. The study enrolled 478 patients and ran for up to 60 weeks, with a minimum of 24 weeks of treatment. Secondary endpoints showed clinically meaningful gains: forced expiratory volume in one second (FEV₁) increased by 122 mL for the 100 mg cohort and 139 mL for the 400 mg cohort, while exhaled nitric oxide (FeNO) fell by 20.4 ppb and 26.3 ppb, respectively. More than 90% of participants transitioned to the long‑term extension study, VALOUR, underscoring tolerability and sustained safety.
The safety profile was consistent with prior studies, with no new or serious adverse events reported. The robust efficacy and favorable safety data reinforce the company’s strategy to advance verekitug into Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The 100 mg every‑12‑week regimen offers a dosing advantage over existing biologics such as Tezspire, which requires monthly injections, potentially improving patient adherence and market appeal.
Management highlighted the significance of the results. Chief Medical Officer Aaron Deykin said the data “provide a strong foundation as we advance verekitug into Phase 3 clinical trials as quickly as possible.” Chief Executive Officer Rand Sutherland emphasized disciplined execution and the company’s transition to a late‑stage development focus. Analysts at William Blair noted that the 56% AAER reduction meets Upstream’s base‑case scenario and positions verekitug as a competitive alternative to Tezspire, with a simpler autoinjector schedule and comparable efficacy.
The company plans to launch Phase 3 studies in 2027, while continuing parallel development in CRSwNP and COPD. Upstream’s cash reserves are projected to fund operations through 2027, supporting the accelerated development timeline. The trial’s success also strengthens Upstream’s competitive positioning in the severe asthma market, where unmet needs remain high and the biologic landscape is crowded with Dupixent and Nucala.
Investors reacted positively to the data, citing the 56% reduction in exacerbations and the differentiated dosing schedule as key drivers. Analysts praised the trial’s statistical significance and the high patient rollover rate, interpreting the results as a milestone that could accelerate regulatory discussions and market entry for verekitug.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.